Securities code: 300199 securities abbreviation: Hybio Pharmaceutical Co.Ltd(300199) Announcement No.: 2022-007 Hybio Pharmaceutical Co.Ltd(300199)
Announcement on the company's re obtaining the certification of high-tech enterprises
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Hybio Pharmaceutical Co.Ltd(300199) (hereinafter referred to as "the company" or " Hybio Pharmaceutical Co.Ltd(300199) ") learned from the high-tech enterprise recognition management network on January 17, 2022 that the company has completed the filing of the second batch of high-tech enterprises in 2021. The company again obtained the certificate of high tech enterprise jointly issued by Shenzhen Science and technology innovation Commission, Shenzhen Finance Commission, State Administration of Taxation and Shenzhen Taxation Bureau. The certificate number is gr202144205879 and the issuing date is December 23, 2021.
According to the administrative measures for the recognition of high-tech enterprises and the enterprise income tax law of the people's Republic of China, the company can continue to enjoy the national preferential tax policies on high-tech enterprises for three years (2022, 2023 and 2024) from the year when it is recognized as a high-tech enterprise, that is, the enterprise income tax shall be paid at the tax rate of 15%.
The company has made tax declaration at the tax rate of 15% in 2021, and the above preferential tax policies will not affect the company's business performance in 2021.
It is hereby announced.
Hybio Pharmaceutical Co.Ltd(300199) board of directors January 18, 2022